Drug Shortages 2011: Can the Global Market Fix This?

US Drug Shortages

US Drug Shortages

Drug shortages are at their highest in the United States, with little indication that these shortages will be remedied anytime soon. Is there anyway that the global market can fix this while becoming an industry leader in the health manufacturing sector?

What’s the Extent of these Drug Shortages?

Drug shortages in the US, which reached record highs in 2010 and the effects of  the 2011  drug shortages have been felt most acutely in oncology, emergency medicine, anesthesia and cardiology. An October report from the Federal Drug Administration has reported that the number of drug shortages annually has tripled from 61 in 2005 to 178 in 2010. Currently, there are 168 drugs that are in short supply. Some cardiology drugs affected by the shortages include amiodarone, digoxin, diltiazem, furosemide, heparin sodium, nitroglycerin, reteplase (Retavase, Centocor), ticlopidine (Ticlid, Roche Palo) and torsemide. Other medications listed as part of drug shortages 2011 include azithromycin, norepinephrine, ketorolac, fentanyl and epinephrine, ciprofloxacin, dopamine, lidocaine and gentamicin.

Why Are These Drug Shortages Happening?

Many reasons have been cited for these 2011 drug shortages. A recent study from the IMS Institute found that health manufacturing problems, discontinuations and suspension of production, inability to meet demand, raw material problems, and contamination or other quality issues are particularly relevant. Business decisions by manufacturers and industry leaders, often involving profitability, also play a key role in shortages, and this issue extends beyond the low return on investment of generics. For instance, production infrastructure and schedules are designed to maximize output of product, and when drug shortages exist and capacity needs to expand, changes cannot be simply imposed upon this structure to correct deficiencies.

Manufacturer discontinuation has also been a major cause of the 2011 drug shortages. In many cases, the manufacturer made a business decision to stop producing a particular compound because the medication was off patent and no longer returning a large profit. This is where the global market and industry leaders can step in to fill the void and possibly fix these drug shortages.

Where the Global Market Can Step In to Remedy Drug Shortages 2011

Growth in demand for contract manufacturing services will continue throughout this decade, especially since there’s little evidence that American drug companies will remedy these drug shortages. The US – the largest market – accounts for more than 40 percent of demand. Due to low overhead for staffing and technical capabilities, India is strongly positioned to capture a significant portion of the growing market.

Several factors will contribute to growth in the global contract manufacturing market including U.S. tax rates, reduction of risk in the supply chain, and multiple contract manufacturing partners, which alleviate supply issues. Increased costs for drug development, the fracturing of the blockbuster business model, the opportunity to improve communication worldwide, and increased global competition will help make outsourcing and off-shoring easier. The global contract manufacturing market is growing at a rate of about 10% annually. This market is projected to more than double in value during the next 10 years as companies increase outsourcing to cut costs and to offset problems related to the drug shortages and health manufacturing.

Photo Source: http://www.ibtimes.com

Avatar
Carrie Ann
Carrie Ann is Editor-in-Chief at Industry Leaders Magazine, based in Las Vegas. Carrie covers technology, trends, marketing, brands, productivity, and leadership. When she isn’t writing she prefers reading. She loves reading books and articles on business, economics, corporate law, luxury products, artificial intelligence, and latest technology. She’s keen on political discussions and shares an undying passion for gadgets. Follow Carrie Ann on Twitter, Facebook

Recent Posts

Herman Miller acquires Knoll for $1.8 billion

Herman Miller acquires Knoll for $1.8 billion

Furniture design giant Herman Miller, Inc. announced its $1.8 billion acquisition of competitor Knoll Inc. on Monday. The acquisition comes at a time when the world is undergoing a
10 hours ago
What to expect from Apple’s Spring Loaded Event on April 20

What to expect from Apple’s Spring Loaded Event on April 20

On April 20, Apple CEO Tim Cook will take the stage to walk us down memory lane. The company’s ‘Spring Loaded’ event on Tuesday will usher in the launch of Apple’s next-gen
14 hours ago
Facebook’s Clubhouse clone to launch in summer

Facebook’s Clubhouse clone to launch in summer

Facebook Inc. on Monday announced it will launch several audio-centric products that can help it compete against Clubhouse, an audio-only chatting app that exploded in popularity d
14 hours ago
IBM revenue beats estimates, buoyed by cloud strength

IBM revenue beats estimates, buoyed by cloud strength

During IBM’s earnings call with analysts, Krishna said he knew that the January transformation in IBM’s strategy to invite more ecosystem partners would “take time for result
18 hours ago
Goldman Sachs invests $69 million in fintech Starling

Goldman Sachs invests $69 million in fintech Starling

Goldman Sachs Growth Equity has invested £50 million ($69 million) in UK digital bank, Starling. The investment is in addition to the bank’s oversubscribed £272 million Ser
1 day ago
Apple to launch hybrid TV set-top with speaker

Apple to launch hybrid TV set-top with speaker

Apple is bolstering its smart home devices space with the introduction of a new hybrid device— a combination of an Apple TV and a smart speaker with a screen, according to news r
2 days ago